Boosting with variant-matched vaccines: an opportunity to win the race against Omicron | Signal Transduction and Targeted Therapy
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect
Real-World Association Between mRNA Vaccination and Infection From the Omicron Strain of SARS-CoV-2: A Population-Level Analysis - AJPM Focus
Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19
CDC - COVID-19 BOOSTER UPDATE: Everyone ages 18+ is eligible for a COVID-19 booster. If you got an mRNA vaccine, either Pfizer-BioNTech or Moderna, you may get a booster dose 6 months
Study: Booster dose of mRNA COVID vaccine prompts strong T cell response in immunocompromised patients
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination | NEJM
COVID-19 mRNA booster provides additional protection, most beneficial for older adults
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR
Vaccini a mRNA Anti COVID-19: Come Funzionano, Efficacia e Sicurezza
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
India-made mRNA vaccine priced at ₹2,292, will be available as a booster dose - The Hindu
CDC - UPDATED: CDC updated booster recommendations for... | Facebook
JCI - Durability of immune responses to mRNA booster vaccination against COVID-19
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice - ScienceDirect
Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | medRxiv
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study | The BMJ
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
